IND approval gives celiac patients possibility to eat gluten

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Paul Bradbury)
(Image: Getty/Paul Bradbury)

Related tags: celiac, Biologics, IND applications, Fda, FDA approval


The FDA approves an IND application from ActoBio for AG017, an oral biologic drug candidate for the reversal of celiac disease, a condition which currently has no approved treatments.

The US Food and Drug Administration (FDA) approved an investigational new drug (IND) for oral ActoBiotics AG017 capsules from ActoBio Therapeutics.

The drug contains a form of bacterium Lacotococcus lactic, which is specifically engineered to express a gliadin peptide in combination with an immunomodulating cytokine.

ActoBiotics programs are currently used to induce antigen-specific immune tolerance that can prevent or reverse certain autoimmune and allergic diseases. AG017 is an antigen-specific investigational immunotherapy candidate with the potential to reverse gluten sensitivity, ActioBio stated.

The drug will enter a Phase Ib/IIa study in patients with celiac disease in the US and Europe later in 2019.

The ActoBio approach enables biologics to be orally or topically administered to provide an alternative means of delivery over injectable biologics.

Celiac disease is a chronic intestinal inflammatory disorder that is caused by an autoimmune reaction triggered by the ingestion of gluten proteins. According to the company, over 90% of patients with celiac disease have an HLA-DQ2.5 genotype that responds to its immunomodulating cytokine.

There is currently no FDA-approved drug for the disease, but many patients live with a strict diet that eliminates all gluten. However, ActoBio suggested that its investigational treatment may allow patients to no longer need to remove gluten from their diets.

Related news

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars